Lung Cancer diagnostic solutions

Lung Cancer diagnostic solutions

1 Lung Cancer diagnostic solutions 1 ALK D5F3 518-111175 790-4843 c-met SP44 518-108830 760-4430 SP65 518-109615 790-4467 CD56 MRQ-42 518-110710 760-4596 CEA TF3H8-1 2 518-110130 760-2507 CEA CEA31 518-111779 760-4594 LK2H10 518-100964 760-2519 Cytokeratin 5 SP27 518-111939 760-4935 5/6 D5/16B4 518-109851 790-4554 Cytokeratin 5/14 EP1601Y/LL002 518-111946 760-4939 / Cytokeratin 14 SP53 519-111366 760-4805 7 SP52 518-100902 790-4462 20 SP33 518-101152 790-4431 Cytokeratin CAM5.2 518-110222 790-4555 EGFR 3C6 518-102432 790-2988 EGFR 5B7 518-109134 790-4347 EGFR E746-A750 del SP111 518-110796 790-4650 EGFR L858R SP125 518-110802 790-4649 EMA E29 518-109684 790-4463 Epithelial Related Antigen, ERA MOC-31 518-110277 790-4561 Epithelial Specific Antigen, Ep-CAM Ber-EP4 518-110260 760-4383 IGF-1R G11 518-109141 790-4346 Mesothelial Cell HBME-1 518-110307 760-4445 Napsin A MRQ-60 518-111601 760-4867 NSE MRQ-55 518-110918 760-4786 p40 BC28 518-112981 790-4950 P63 4A4 518-101961 790-4509 Cytokeratin Pan-keratin AE1, AE3, PCK26 3 518-110178 760-2595 Synaptophysin MRQ-40 518-110864 760-4595 TAG-72 B72.3 518-101459 760-2669 TTF-1 SP141 518-110871 790-4756 WT-1 6F-H2 518-108755 760-4397 1 2 I-VIEW CEA TF3H8-122500AMX01061000 ultraview CEA TF3H8-122500AMX01060000 3 I-VIEW Cytokeratin Pan-keratin AE1,AE3,PCK2622500AMX00911000 ultraview Cytokeratin Pan-keratin AE1,AE3,PCK2622500AMX00906000

Lung Cancer diagnostic solutions 2 1 5 5 89% NSCLC80 85% 1 SCLC15 20% 1 3 EGFR ALK 4 15% 2 NSCLC SCLC 15% 1 NSCLC 85% 1 5 30% H&E 6 60% 1 40% 1 EGFR ALK KRAS PD-L1 ROS1

3 Lung Cancer diagnostic solutions NSCLC Squamous cell carcinoma stained with p40 BC28 using OptiView DAB IHC detection Squamous cell carcinoma stained with CK 5/6 D5/16B4 p40bc28 5/6D5/16B4 p40 ( BC28) P63 7,8 p40 BC28 Cytokeratin 5/6 TTF-1 Napsin A 9 5/6D5/16B4 5 6 5 6 Squamous cell carcinoma stained with P63 4A4 Squamous cell carcinoma stained with CK 5/14 EP1601Y/LL002 P634A4 P634A4 p63 Cytokeratin 5/14 EP1601Y/LL002 5 14

Lung Cancer diagnostic solutions 4 NSCLC Adenocarcinoma stained with TTF-1 SP141 Adenocarcinoma stained with Napsin-A MRQ-60 TTF-1SP141 Napsin AMRQ-60 TTF-1 TTF-1SP141 Napsin A Napsin A Napsin A TTF-1SP141 SP141 8G7G3/1 YeNapsin A Napsin A TTF-1 2 10 Dr. Shalini Singh Ventana Medical Systems

5 Lung Cancer diagnostic solutions NSCLC ALK c-met Adenocarcinoma stained with ALK D5F3 Adenocarcinoma stained with c-met SP44 ALKD5F3 c-metsp44 ALKD5F3 ALK c-metsp44 c-met ALKD5F3 NSCLC ALK ALK296 D5F3 ALK FISH 100% 11 HGF MET ADC70% SCC 40% c-met c-met 12 IHC SP44 318 55 17.3% IHCALK FFPEMET 55 3 13 FISH 11

Lung Cancer diagnostic solutions 6 NSCLC EGFR Adenocarcinoma stained with EGFR 3C6 Adenocarcinoma stained with EGFR 5B7 Adenocarcinoma stained with EGFR E746-A750 del SP111 Adenocarcinoma stained with EGFR L858R SP125 EGFR EGFR EGFR E746-A750 del EGFR L858R 3C6 5B7 SP111 SP125 EGFR3C6 EGFR5B7 EGFR E746-A750 del EGFR L858R 170 kd EGFR EGFR SP111 SP125 IgG1 145 kd III EGFR EGFR EGFR E746-A750 del EGFR L858R EML4-ALK EGFR 11,12 ALK EGFR 13-16 2EGFR EGFR 17

7 Lung Cancer diagnostic solutions NSCLC p40 BC28 P63 4A4 5/6 D5/16B4 Cytokeratin 5/14 EP1601Y/LL002

Lung Cancer diagnostic solutions 8 TTF-1 SP141 Napsin A MRQ-60 ALK ALK D5F3

9 Lung Cancer diagnostic solutions SCLC CD56MRQ-42 SP65 CD56MRQ-42 NK NK T LK2H10 7SP52 C 7SP52 7 7 NSEMRQ-55 20SP33 NSE 20SP33 18 SynaptophysinMRQ-40 WT16F-H2 SynaptophysinMRQ-40 WT111p13 WT16F-H2

Lung Cancer diagnostic solutions 10 1., ganjoho.jp 2. National Cancer Institute. General Information About Small Cell Lung Cancer. 2013; http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/ healthprofessional. 3. NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer. Version 2. 2013 4. Pao W, Hutchinson KE. Chipping Away at the Lung Cancer Genome. Nat Med 18 3 :349-351. 2012. 5. Tacha D, Yu C, Bremer R, Qi W, Haas T. A 6-antibody panel for the classification of lung adenocarcinoma versus squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20:201-207. 15. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275-4283. 16. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22:508-515. 17. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723-1733. 18. Leong AS, Phillips GE, Pieterse AS, Milios J.Criteria for the diagnosis of primary endocrinecarcinoma of the skin Merkel cell carcinoma. A histological, immunohistochemical andultrastructural study of 13 cases. Pathology. 1986;18:393-399. 6. Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol. 2009;4:1202-1211. 7. Bishop, Justin A, Julie Teruya-Feldstein, William H Westra, Giuseppe Pelosi, William D Travis and Natasha Rekhtman. p40np63 is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathology. 2012. 8. Chen, Xiangbai, Yunhau Bao, Rebecca Wong, Katerina Politi, Lizhuo Jiao, Scott Gettinger, Robert Homer, David Chieng, Guoping Cai. [351] The Role of p40 Immunostain in the Cytological Differential Diagnosis of Squamous Cell Carcinoma and Adenocarcinoma of the Lung. USCAP Abstract. 2013. 9. Wei Zhao, Hui Wang, Yan Peng, Bo Tian, Lei Peng, Da-Chuan Zhang. Np63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol 2014;7 7 :4247-4253 10. Ye et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastaticcarcinoma in the lung. Appl Immunohistochem Mol Morphol. 2011 Jul;19 4 :313-7. doi: 10.1097/ PAI.0b013e318205b059. 11. Minca et al. ALK Status Testing in Non Small Cell Lung Carcinoma Correlation Between Ultrasensitive IHC and FISH. J Mol Diagn. 2013; 15 3. http://dx.doi.org/10.1016/j. jmoldx.2013.01.004. 12. Tsuta K, Kozu Y, Mimae T, et al. c-met/ phospho-met protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol. 2012;7:331-339. 13. Koeppen H, Januario T, Filvaroff E. Characterization and clinical validation of an immunohistochemical assay for Met in non-small cell lung cancer. Mod. Pathol. 2012; 25; 480A. 14. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247-4253.

105-0014 2-6-1 http://www.roche-diagnostics.jp 0120-868-555 VENTANA 1059.TD.TMS.1700.GEN01-003A